{"id":109538,"date":"2023-09-11T11:51:11","date_gmt":"2023-09-11T06:21:11","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=109538"},"modified":"2023-09-11T11:51:33","modified_gmt":"2023-09-11T06:21:33","slug":"glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/","title":{"rendered":"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2701925558\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1158469944\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The Mumbai-based pharmaceutical giant is also aiming to increase EBITDA margins while extending its reach into more therapeutic areas like dermatology and oncology.<\/p><p>&#8220;For the new financial year, we aim to grow by 10-11 per cent in revenues, expand our EBITDA margin to 19-20 per cent, and continue to focus on enhancing free cash generation for further debt reduction,&#8221; Saldanha said in the company&#8217;s Annual Report for FY23.<\/p><p>The company&#8217;s consolidated revenue from operations stood at Rs 12,990 crore in FY23, increased from Rs 12,305 crore in FY22.<\/p><div class=\"trade-content_5\" id=\"trade-377483722\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Besides, the drug maker posted an EBITDA of Rs 2,278 crore during the 2022-23 fiscal with margins at 17.5 per cent. <strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/GLENMARK\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Glenmark<\/a><\/strong> posted net debt of Rs 2,905 crore for the fiscal ended March 31, 2023.<\/p><p>Addressing the company&#8217;s shareholders, he noted that the company will identify potential candidates for development purposes on a global scale as the drug maker moves up the value chain.<\/p><p>&#8220;Simultaneously, we are working towards enhancing our dermatology, oncology, and respiratory portfolios to establish a formidable presence in these core therapy areas through timely launches,&#8221; Saldanha informed shareholders.<\/p><p>He noted that differentiated products will be at the forefront of the company&#8217;s new launches in FY 24 to gain a competitive edge.<\/p><p>&#8220;These will help us expand our presence in the branded\/specialty\/complex segments,&#8221; Saldanha stated.<\/p><p>On plants facing regulatory issues, he stated: &#8220;Goa, Baddi, and Monroe (US) will continue their remediation efforts at the same momentum, and be inspection-ready this financial year.&#8221;&nbsp;<\/p><div class=\"trade-content-10\" id=\"trade-4027568221\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>He further said: &#8220;We are mindful of the fact that as our scale of operations continues to increase, it becomes even more imperative to be quality-focused and compliant.&#8221; Elaborating on its formulations business in North America, the company said it plans to file 10-12 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration in the current fiscal.<\/p><p>In FY23, By the US health regulator, Glanmark was granted approval of 10 ANDAs.<\/p><p>On Monday at 11.40 a.m. shares of the company were trading 2.4% up at Rs. 795.60 on NSE.<\/p><div class=\"trade-after-content\" id=\"trade-3015599574\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.&nbsp; The Mumbai-based pharmaceutical giant is also aiming to increase EBITDA margins while extending its reach into more therapeutic areas like dermatology and [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":106029,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1696,31],"tags":[],"class_list":["post-109538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-action","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24\" \/>\n<meta property=\"og:description\" content=\"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T06:21:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-11T06:21:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/\",\"url\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/\",\"name\":\"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg\",\"datePublished\":\"2023-09-11T06:21:11+00:00\",\"dateModified\":\"2023-09-11T06:21:33+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24 - Trade Brains Features","description":"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/","og_locale":"en_US","og_type":"article","og_title":"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24","og_description":"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-09-11T06:21:11+00:00","article_modified_time":"2023-09-11T06:21:33+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/","url":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/","name":"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg","datePublished":"2023-09-11T06:21:11+00:00","dateModified":"2023-09-11T06:21:33+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"According to Chairman and Managing Director Saldanha, Glenmark Pharmaceuticals targets to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/08\/glenmark.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/glenmark-plans-to-focus-on-free-cash-flow-generation-and-debt-reduction-company-eyes-double-digit-revenue-growth-in-fy24\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Glenmark plans to focus on free cash flow generation and debt reduction; Company eyes double-digit revenue growth in FY24"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=109538"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109538\/revisions"}],"predecessor-version":[{"id":109543,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109538\/revisions\/109543"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/106029"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=109538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=109538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=109538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}